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Abstract
Colorectal cancer is fairly common compared to other cancers. The incidence and mortality rates are predicted to increase 
globally. In some cases, cancer can be potentially spread to another organ or metastatic. One of recent available targeted 
therapies for metastatic colorectal cancer (mCRC) patient is Cetuximab (Erbitux ®), combined with chemotherapy. Despite 
clinical effectiveness, there is the importance of the evidence related cost-effectiveness of therapy. This study aims to 
summary, synthesize, and systematically review the economic evaluation studies of Cetuximab for metastatic colorectal 
cancer (mCRC). Model based economic evaluation of Cetuximab for metastatic colorectal cancer will be searched and 
included in the review based on specific eligibility criteria. Several electronic databases that will be used: Medline, Embase, 
Cochrane, National Institute of Health Research (NIHR) Center for Reviews and Dissemination. Full economic evaluation 
evidence will be summarized and critically appraised using Drummond as well as (Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS) checklist. In terms of analysis, we will qualitatively appraise and present the studies that meet 
our inclusion and exclusion criteria. We are expected to summarize the quality and capture the valuable insights related to 
health economic evaluation studies of Cetuximab for mCRC patient. 
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Abstrak
Kanker kolorektal cukup umum terjadi dibandingkan kanker lainnya, angka kejadian dan angka kematian diprediksi meningkat secara 
global. Dalam beberapa kasus, kanker berpotensi menyebar ke organ lain atau disebut metastasis. Salah satu terapi yang ditargetkan 
baru-baru ini untuk pasien kanker kolorektal metastatik (mCRC) adalah Cetuximab (Erbitux®), yang dikombinasikan dengan kemoter-
api. Meskipun terdapat bukti klinis, penting untuk mempertimbangkan bukti terkait efektivitas biaya dari terapi tersebut. Penelitian ini 
bertujuan untuk merangkum, mensintesis, dan meninjau secara sistematis studi evaluasi ekonomi Cetuximab untuk kanker kolorektal 
metastatik (mCRC). Evaluasi ekonomi berbasis model untuk menilai Cetuximab pada kanker kolorektal metastatik akan ditelusuri 
sesuai dengan kriteria yang ditetapkan. Beberapa database elektronik yang akan digunakan: Medline, Embase, Cochrane, Pusat Pene-
litian Kesehatan Nasional (NIHR) untuk Tinjauan dan Diseminasi. Bukti evaluasi ekonomi lengkap akan dirangkum dan dinilai secara 
kritis dengan menggunakan daftar pertanyaan Drummond dan juga Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS). Dalam hal analisis, kami akan menilai dan menyajikan secara kualitatif studi yang memenuhi kriteria inklusi dan eksklusi. 
Kami berekspektasi untuk menyimpulkan kualitas dan menangkap informasi yang berkaitan dengan studi evaluasi ekonomi pada 
Cetuximab untuk pasien mCRC.
Kata kunci: evaluasi ekonomi, Cetuximab, Erbitux, kanker kolorektal
IntroductionColorectal cancer (CRC) is one of the most common cancer worldwide, with approximately 1.4 million new cases that were diagnosed in 2012. It is pre-dicted that the disease burden will increase for more than 2.2 million new cases and 1.1 million deaths in 2030 (Ferlay et al, 2012; Arnold et al 2016). The incidence rates have been rising in developing countries, even though colorectal cancer as historical were commonly diagnosed in developed world. The 
aging population, unhealthy lifestyle and behaviors, gender, geographical variations as well as economic status may become considerably factors that impact-ed the global burden of this disease (Favoriti et al 2016; Douaiher et al 2017).Over the past two decades, almost 20% patients with CRC already have metastases in diagnosis. Sim-ilar with other types of cancer, CRC can be spread to other parts of patients’ body (van der Geest et 
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al 2015). The most frequent is liver, sometimes it spreads to the lungs, bones, or other organs in the body (Field and Lipton 2007). Most of metastatic colorectal cancer (mCRC) have been not possible to be cured,  and palliative care is become the option in the past decades (Ewara, 2012). On the other hand, surgical procedure is also one of the potential options, however in some clinical cases this could not be done. As consequence, chemotherapy may become the most appropriate one. Furthermore, the treatment generally can be undertaken by perform-ing combination intervention such as: surgical, ra-diotherapy, chemotherapy and another supportive care. Recently, there are introduction of several ad-vancements for targeted therapy, including bevaci-zumab (Avastin®), cetuximab (Erbitux®), and pa-nitumumab (Vectibix®). These targeted therapies 
have potential benefit in terms of improving the patients’ survival-as monotherapy or combination, also depending on treatment patterns (Tappenden et al 2007; Rinaldi et al 2012; Silva et al 2017). In general, most of patients receiving the combina-
tion of 5-fluorouracil(FU)/leucovorin (LV) with containing either oxaliplatin (FOLFOX) or irinote-can (FOLFIRI) together with monoclonal antibody (MAb) has widely-accepted as standard care. The combination of MAb improves the overall survival, progression-free survival as well as tumor response rate (Chan et al, 2017).Cetuximab is one of monoclonal antibodies that target the epidermal growth factor receptor (EGFR) 
and beneficial in order to treat mCRC patients, par-ticularly in patients who had failed with chemother-apy. Epidermal growth factor receptor (EGFR) plays 
important roles in terms of differentiation, survival, normal or cancerous cells. EGFR is a receptor that can be found in both normal and tumor cells (Marti-nelli et al 2009; Yarom and Jonker 2011). As EGFR inhibitor, Cetuximab is used to impede the EGFR activity from growing continuously. Moreover, pa-tients with Kirsten rat sarcoma (KRAS) wild-type tumors characteristic can receive this therapy. It means if KRAS is mutated, the EGFR inhibitor un-likely provide favorable respond to patients. Several studies concluded the additional of cetux-imab to chemotherapy has potentially favorable, al-though not in all expected clinical outcomes. In the Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer (CRYS-TAL) study reported that the additional cetuximab 
to FOLFIRI as first-line treatment potentially in-crease the response chance and reduce the risk of disease progression in with KRAS wild type patients. Compared to FOLFIRI alone, the overall survival (OS) was (median 23.5 vs 20 months; HR= 0.796; P = .0093), progression free survival (PFS) (me-dian, 9.9 vs 8.4 months; HR, 0.696; P = .0012), and response rate (rate 57.3% vs 39.7%; odds ratio, 2.069; P < .001)(Van Cutsem et al, 2011). More-over, the Oxaliplatin and Cetuximab in First-Line 
Treatment of Metastatic Colorectal Cancer (OPUS) 
study reported that addition of cetuximab to 5-flu-orouracil, folinic acid and oxaliplatin (FOLFOX4) 
as first line therapy in mCRC patients has improved the objective response and PFS. For KRAS wild type tumors, compared to FOLFOX4 alone the chance of response has clinically increased (ORR=61% vs 37%; OR=2.54; P=0.011) and lower risk of disease progression (HR=0.57; P=0.0163). (Bokemeyer et 
al, 2009) Both of these studies confirmed that the KRAS mutation is impactful predictive marker for 
the efficacy or outcome when adding the cetuximab with chemotherapy.
The financial burden of colorectal treatment itself are substantial. As the introduction of the new tar-geted therapy caused the treatment expenditures in-creasing, and become the challenges in clinical prac-tice and public health policy (Jansman et al, 2007). In terms of resource allocation and to inform cover-age decision, as this drug provides clinical improve-ment but relatively costly, economic evaluation study will be conducted in Indonesia setting (Indonesian Health Technology Assessment). The assessment is intended to assess “value for money” of Cetuximab for mCRC patients in Indonesia. Furthermore, as the initial step for health economic model development, literature review of related studies is required. The aim of this study is to conduct the review of health economic evaluation studies related Cetux-
imab as first line therapy for mCRC. We will per-form systematic search, summary, narrative and crit-ical review from relevant-available evidence. Several 
studies previously conducted to assess clinical effec-
tiveness and some cost-effectiveness of this therapy 
with various comparators and specific population criteria(Tappenden et al, 2007; Gao et al, 2009; Yang et al, 2017). Therefore, we plan to conduct comprehensive review that potentially useful not only to gather the information in order to support our economic model structure, but also to sharpen our critical appraisal skill. As our study assumption, 
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we specify the review activity to cetuximab plus che-
motherapy as first-line treatment compared to che-
motherapy alone. The clinical effectiveness review is conducted elsewhere, with similar team member. 
Method
Operational DefinitionsColorectal cancer happens when the abnormal cells are growing in colon or rectum. It is often starter 
with polyp, the overgrowth of the cells and finally 
turn to cancer. When the cancer spreads or familiarly known as “metastatic”, the most often organs that is impacted is liver, sometimes it also spread to the lungs, bones, or other organs in the body(NCCN, version 1.2017). Cetuximab (Erbitux ®) is “a chimeric monoclonal antibody highly selective for the epidermal growth factor receptor (EGFR), which is over-expressed by 25-80% of colorectal cancer tumors and associated 
with advanced disease”. (Reynolds and Wagstaff, 
2004) EGFR is a protein that influence the grow of cancer cell, it appears on the surface of cancer cells, Cetuximab target EGFR, it is given by IV infusion. Several colorectal cancers have mutations in the KRAS or BRAF gene, that make Cetuximab 
ineffective(Laurent-Puig et al, 2009).
Economic evaluation is defined as “comparative analysis of alternative courses of action in terms of both their costs and consequences”, it provides evidence whether the health intervention is worth 
or efficient use of resources, gaining the best value for money. Economic evaluation consists of full economic evaluation and partial economic evaluation (Drummond et al, 2015).
Inclusion and Exclusion CriteriaIn terms of inclusion criteria, we will include full 
economic evaluation studies: cost-effectiveness and cost-utility analysis particularly that performing de-
cision analytic or mathematical model. We remain including the evaluation alongside clinical trial. The population are all mCRC patients (age ≥18 years old, with no restriction on metastatic organs, gender characteristics and race) who had received Cetux-imab (Erbitux®) as first line treatment, added to chemotherapy. No limitation regarding the dose, ad-ministration frequency, and treatment duration. The comparators are standard chemotherapeutic agent 
including: Folinic acid, 5-fluorouracil (5-FU) and 
Oxaliplatin (FOLFOX) and Folinic acid, 5-fluoro-
uracil (5-FU) and irinotecan (FOLFIRI) or other standard chemotherapy (i.e: XELOX). The primary 
outcome of interest must include Incremental Cost 
Effectiveness Ratio (ICER), the ratio calculation of incremental cost to increase additional unit of out-
come/benefit for intervention versus comparators, 
generally represented by costs per QALY or costs/natural unit. 
We exclude the partial economic evaluation stud-ies that only reported cost description, cost analysis or cost of illness. Furthermore, Cetuximab as second or third line therapy for colorectal cancer are ex-cluded for the review. 
Electronic Databases and Searching Methods
The search strategy will be performed for Medline/PubMed, Embase and Cochrane Library (see sup-plementary appendix 1). The searching in database 
specific headings, vocabulary and terms will follow the Center for Reviews and Dissemination’s (CRD) 
Guidance 2009. The first step of searching process is we will perform several related search terms and synonyms about “cetuximab”, “colorectal cancer” and “economic evaluation”. Furthermore, we will apply the Boolean connector including “OR” for each sim-
ilar term/domain and then combine with “AND” to 
make our searching more specific and close to in-clusion criteria. Reference list from main published 
study also checked to find the relevant literature. No restriction in terms of year of publication, and only study that reported in English are collected. Grey literature such as conferences abstract, non-full 
text report/posters are possible to be summarized but not for full review. However, we include the full text of thesis or dissertation if they meet our criteria. 
ResultsThis protocol only provided the information and stages regarding our review plan. The result for narrative review after applying searching strategy will be corresponded with each stage (plan when conducting the review) below:
Study SelectionFor this review, we will have four independent reviewers that would be divided into two groups. SP and ES will screen the titles and abstracts, selecting the studies that potentially meet our eligibility criteria. Another reviewers LC and RS, will be working together with SP and ES for re checking the screening stage before critical review process. The disagreements between reviewers will be resolved by discussion. The details of this selection process will be reported using Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 
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diagram(Moher et al, 2009).
Data ExtractionIn the stage of data extraction, we will use standardized sheet from in Microsoft Excel. Two reviewers will extract the data (LC and RS). The sheet will be used to summarize the important characteristics of studies that meet our eligibility criteria, there are including: the author and year of publication, type of economic evaluation, modeling method, perspective, result (ICER, QALY, costs), and sensitivity analysis. In order to keep our transparency and consistency, the other reviewers will re-check the completed extraction form (AM and VP). 
Quality AssessmentThe quality assessment would be assed by two independent authors (SP and ES) and reviewed 
by a third author (RS). We will use Drummond’s Checklist (Drummond et al., 2015) and Consolidated Health Economic Evaluation Reporting Standard (CHEERS) statement (Husereau et al., 2013).
Data SynthesisAs economic evaluation commonly has the substantial heterogeneity between studies such as: study setting, analysis, perspectives, methods and model assumption, we do attempt to synthesize all included studies, narratively. The objective of this narrative presentation is to identify, critically appraise and compare all studies. In addition, we also try to explore the strengths as well as the weaknesses of each study, with expectation to gain insight for our economic model development.In order to establish the comparison between 
studies, we will convert the cost to 2017 US dollars 
(US$) and adjusted international exchange rates based on Purchasing Power Parity (PPP). The data synthesis and level of evidence are presented based on the check list. For this review, there is no scheme for direct-quantifying the risk of bias of each study, as our objective is only focus to exploring and presenting the narrative review of the economic evaluation studies. 
Discussion
As this intervention have significant economic burden, not only for the health care providers, but also for patient itself as well as societies. (Jansman et al, 2007; Gerber, 2008; Mittmann et al., 2009) The economic evaluation is needed to provide plausible evidence of health technologies and inform decision maker in decision making process. Several studies related economic evaluation of 
targeted therapy with various setting, comparators, and design have been published, such as Bevasizumab (Avastin ®), Panitumumab (Vectibix®) and other therapies (Tappenden et al., 2007; Lange et al., 2014) Currently, we are conducting this review based our need as a part of HTA activity, following our eligibility criteria alongside by discussion with clinicians, practitioners and policy makers. Hence, we provide transparent and systematic way in terms of summarizing the evidence and starting the model construction. 
Conclusion In conclusion, this protocol attempts to provide description as our initial stage for conducting economic evaluation for Cetuximab in mCRC patients. Furthermore, the review of studies also intended to inform and provide description for researchers in our team and respected audience about systematic steps in our HTA studies, particularly to aid model development process. The evidence from health economic evaluation studies is expected to 
provide us beneficial information, and obtaining more comprehensive input in understanding the method, model development, results and as well as research gap. 
Funding: This HTA study is mandated by HTA Indonesia (Center for Health Financing and Insurance) Ministry of Health Republic of Indonesia and funded by Social Security Agency for Health (BPJS) Indonesia. 
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Appendix 1: Sample of search strategy
#1 colorectal neoplasms
#2 colorect* or colon* or rect* or anal* or anus* 
or intestin* or bowel*
#3 #1 or #2
#4 cancer* or tum$r* or carcinom* or sarcom*
#5 #3 and #4
#6 epidermal growth factor or EGR or EFGR or 
Cetuximab or Erbitux
#7 #5 and #6
#8 Economic or economic evaluation or cost ef-
fectiveness or cost utility or CEA or CUA
#9 #7 and #8
Note: The search strategy would be developed more comprehensive as needed
Appendix 2: Drummond’s checklist (Drum-
mond et.,al 2015)
1. Was a well-defined question posed in an answer-able form?• Were both costs and effects examined? • Were alternatives considered? • Was the perspective of the analysis stated? Is the analysis embedded in any decision making context? 2. Was a comprehensive description of the compet-ing alternatives given? • Were any alternatives that were relevant to evaluation omitted? • Was a do-nothing alternative considered or should it be?3. Was the effectiveness of the programmes or ser-vices established?• Was this done through a randomised con-
trolled trial? Did the trial reflect what happens in usual care or routine practice?• Was this done though a systematic review of evidence from clinical studies? If so, was the search strategy including inclusion and exclu-sion criteria clearly described? • Were observational data or assumptions used 
when establishing effectiveness? If so, are there any potential biases in the results? 4. Were all the important and relevant costs and 
consequences for each alternative identified? • Was the range wide-enough for the research question at hand? • Were all relevant perspectives covered (e.g., community, NHS, patient)?
• Were capital costs as well as operating costs included? Capital costs are one-time expenses typically incurred to set up a service Operat-ing costs are the recurrent delivery costs of a 
service, e.g. staff 5. Were costs and effects measured accurately in appropriate physical units (e.g., QALYs)?• Were sources of service utilisation described and acceptable?• Were any items omitted? If so, what effect does this have on the analysis?• Were there any special circumstances that 
made measurement difficult? Were these diffi-culties addressed?6. Were costs and effects valued credibly?• Were all sources of the values clearly identi-
fied?• Were market values employed for changes in-volving resources gained or depleted?• Where market values were absent (e.g. vol-unteer labour) or market values did not re-
flect actual values (e.g. equipment given at a reduced rate), were adjustments made to ap-proximate market values? • Was the valuation of effects appropriate for 
the question posed? Was the appropriate type 
of analysis/analyses (e.g. cost-effectiveness, 
cost-benefit or cost-utility analysis) undertak-en? Market value is the price an asset would fetch in the marketplace 7. Were costs and effects adjusted for differential timing?• Were future costs and effects discounted to their present value?• What was the discount rate used and was the 
justification for this rate specified?8. Was an incremental analysis of costs and effects of alternatives performed?• Were the additional (incremental) costs gen-erated by one alternative over another com-
pared to the additional effects, benefits, or utilities generated?9. Were allowances made for uncertainty in the es-
timates of costs and effects?• Were appropriate analyses undertaken on pa-
tient-level data of costs and effects?• If sensitivity analyses were undertaken, were 
the justification for the ranges and distribu-tion of values chosen (for key parameters) 
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specified and explained?• Were conclusions drawn sensitive to uncer-
tainty from the statistical and/or sensitivity analyses? 10. Did the presentation and discussion of study results include all issues of concern to users? - 
Were conclusions of the analysis based on an in-
dex or ratio (e.g. cost-effectiveness or cost-bene-
fit ratio)? Was this ratio interpreted intelligently or in a mechanistic fashion?• Were the results compared with those of oth-ers who have investigated the same question? If so, were allowances made for potential dif-ferences in methodology?
• Did the study discuss the potential of gener-alisability of the results to other settings or 
patient/population groups?• Did the study take in account other important factors in the choice or decision under consid-
eration (e.g. ethical issues, limited staff num-bers or wider policy context and relevance)?• Did the study discuss issues of implementa-tion (e.g. feasibility of adopting recommenda-tions)? Are there any potential issues regard-
ing finance and resources? Could resources be relocated from other areas to assist the imple-mentation?
Appendix 3: CHEERS checklist (Husereau et al., 2013)
CHEERS checklist—Items to include when reporting economic evaluations 
of health interventions
Section/item Item No Recommendation Page/Comment
Title 1
Identify the study as an economic evaluation or use more 
specific terms such as “cost-effectiveness analysis”, and de-
scribe the interventions compared.
Abstract 2
Provide a structured summary of objectives, perspective, 
setting, methods (including study design and inputs), results 
(including base case and uncertainty analyses), and conclu-
sions.
Background and objec-
tives 3
Provide an explicit statement of the broader context for the 
study.
Present the study question and its relevance for health policy 
or practice decisions.
Target population and 
subgroups 4
Describe characteristics of the base case population and 
subgroups analysed, including why they were chosen.
Setting and location 5 State relevant aspects of the system(s) in which the deci-sion(s) need(s) to be made.
Study perspective 6 Describe the perspective of the study and relate this to the costs being evaluated.
Comparators 7 Describe the interventions or strategies being compared and state why they were chosen.
Time horizon 8 State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.
Discount rate 9 Report the choice of discount rate(s) used for costs and out-comes and say why appropriate.
Choice of health out-
comes 10
Describe what outcomes were used as the measure(s) of 
benefit in the evaluation and their relevance for the type of 
analysis performed.
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Section/item Item No Recommendation Page/Comment
Measurement of effec-
tiveness
11a
Single study-based estimates: Describe fully the design 
features of the single effectiveness study and why the single 
study was a sufficient source of clinical effectiveness data.
11b
Synthesis-based estimates: Describe fully the methods used 
for identification of included studies and synthesis of clinical 
effectiveness data.
Measurement and 
valuation of preference 
based outcomes
12 If applicable, describe the population and methods used to elicit preferences for outcomes.
Estimating resources 
and costs
13a
Single study-based economic evaluation:Describe approaches 
used to estimate resource use associated with the alterna-
tive interventions. Describe primary or secondary research 
methods for valuing each resource item in terms of its unit 
cost. Describe any adjustments made to approximate to 
opportunity costs.
13b
Model-based economic evaluation: Describe approaches and 
data sources used to estimate resource use associated with 
model health states. Describe primary or secondary research 
methods for valuing each resource item in terms of its unit 
cost. Describe any adjustments made to approximate to 
opportunity costs.
Currency, price date, 
and conversion 14
Report the dates of the estimated resource quantities and 
unit costs. Describe methods for adjusting estimated unit 
costs to the year of reported costs if necessary. Describe 
methods for converting costs into a common currency base 
and the exchange rate.
Choice of model 15
Describe and give reasons for the specific type of deci-
sion-analytical model used. Providing a figure to show 
model structure is strongly recommended.
Assumptions 16 Describe all structural or other assumptions underpinning the decision-analytical model.
Analytical methods 17
Describe all analytical methods supporting the evaluation. 
This could include methods for dealing with skewed, miss-
ing, or censored data; extrapolation methods; methods for 
pooling data; approaches to validate or make adjustments 
(such as half cycle corrections) to a model; and methods for 
handling population heterogeneity and uncertainty.
Study parameters 18
Report the values, ranges, references, and, if used, probabili-
ty distributions for all parameters. Report reasons or sources 
for distributions used to represent uncertainty where appro-
priate. Providing a table to show the input values is strongly 
recommended.
Incremental costs and 
outcomes 19
For each intervention, report mean values for the main 
categories of estimated costs and outcomes of interest, as 
well as mean differences between the comparator groups. If 
applicable, report incremental cost-effectiveness ratios.
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Section/item Item No Recommendation Page/Comment
Characterising uncer-
tainty
20a
Single study-based economic evaluation:Describe the effects 
of sampling uncertainty for the estimated incremental cost 
and incremental effectiveness parameters, together with the 
impact of methodological assumptions (such as discount 
rate, study perspective).
20b
Model-based economic evaluation: Describe the effects on the 
results of uncertainty for all input parameters, and uncer-
tainty related to the structure of the model and assumptions.
Characterising hetero-
geneity 21
If applicable, report differences in costs, outcomes, or 
cost-effectiveness that can be explained by variations be-
tween subgroups of patients with different baseline charac-
teristics or other observed variability in effects that are not 
reducible by more information.
Study findings, limita-
tions, generalisability, 
and current knowledge
22
Summarise key study findings and describe how they sup-
port the conclusions reached. Discuss limitations and the 
generalisability of the findings and how the findings fit with 
current knowledge.
Source of funding 23
Describe how the study was funded and the role of the 
funder in the identification, design, conduct, and reporting 
of the analysis. Describe other non-monetary sources of 
support.
Conflicts of interest 24
Describe any potential for conflict of interest of study con-
tributors in accordance with journal policy. In the absence 
of a journal policy, we recommend authors comply with 
International Committee of Medical Journal Editors recom-
mendations.
